Tagrisso
Hutchmed Submits NDA in China for Orpathys, Tagrisso Combo in EGFR, MET-Driven NSCLC
The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.
AstraZeneca Nabs FDA Approval for Tagrisso in Stage III, Unresectable EGFR-Mutated NSCLC
The third-generation EGFR inhibitor will now be an option for patients whose tumors are not metastatic but can't be removed with surgery.
FDA Grants AstraZeneca's Tagrisso sNDA Priority Review in Unresectable Stage III NSCLC
The firm filed data showing Tagrisso reduced the risk of disease progression or death by 84 percent versus placebo in patients with EGFR-mutated tumors.
CHMP Recommends AstraZeneca's Tagrisso, Chemo for Advanced EGFR-Mutated NSCLC
The committee recommended the combination after seeing that it reduced the risk of disease progression or death by 38 percent compared to just Tagrisso.
Tagrisso Poised to Become Standard of Care in Unresectable Stage III EGFR-Mutated NSCLC
In the LAURA trial presented at ASCO, AstraZeneca's EGFR inhibitor led to an 84 percent reduction in the risk of disease progression or death versus placebo.
Oct 24, 2023